Clinical Research Directory
Browse clinical research sites, groups, and studies.
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
Sponsor: Royal College of Surgeons, Ireland
Summary
RECOVER is a prospective, multicenter observational study designed to measure the real world clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) triple combination therapy in people with cystic fibrosis initially over a two year period, followed by a five year extension period. Measured outcomes include measures of lung function, lung inflammation, lung imaging, abdominal symptoms, gut inflammation, liver function, pancreatic exocrine function, nasal inflammation, quality of life and adherence to therapy. The study will examine outcomes in two cohorts, children aged six to eleven years and children and adults aged twelve and above.
Key Details
Gender
All
Age Range
6 Years - Any
Study Type
INTERVENTIONAL
Enrollment
206
Start Date
2020-09-03
Completion Date
2029-07-01
Last Updated
2026-09-09
Healthy Volunteers
No
Conditions
Interventions
Elexacaftor/Tezacaftor/Ivacaftor
The intervention is the same for both study groups. In addition to all the assessments in the standard arm, the advanced arm subjects will undergo spirometry controlled CT, nasal lavage and sputum sample collection.
Locations (7)
Children's Health Ireland at Crumlin
Dublin, Leinster, Ireland
University Hospital Limerick
Limerick, Limerick, Ireland
Children's Health Ireland at Temple Street
Dublin, Ireland
St. Vincent's University Hospital
Dublin, Ireland
Children's Health Ireland at Tallaght
Tallaght, Ireland
Royal Belfast Hospital for Sick Children
Belfast, United Kingdom
Royal Brompton Hospital
London, United Kingdom